bioPulse

Clinical trial results are dense, and most retail investors in biotech do not have the training to read them. bioPulse is an AI research tool for biotech investing that turns trial data into plain summaries built for people buying and selling small-cap biotech stocks without a scientific background. bioPulse also summarizes SEC filings and the competitive landscape around a company, so you can see what a drug candidate is up against without reading every document yourself.

It points out potential investment opportunities and offers insights meant to inform your own decisions.

Two catches.

The platform is in private beta, so access is limited and you may have to wait.

And it does not give investment advice.

Its analysis comes from AI, which means you should check anything important against the source material and apply your own judgement before putting money behind it.